Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
Žáčková D, Semerád L, Faber E, Klamová H, Stejskal L, Bělohlávková P, Karas M, Cmunt E, Černá O, Procházková J, Čičátková P, Kvetková A, Horňák T, Skoumalová I, Srbová D, Šálek C, Buffa D, Voglová J, Jurček T, Folta A, Ježíšková I, Žižková H, Machová Poláková K, Papajík T, Žák P, Jindra P, Svobodník A, Štěpánová R, Mayer J. Žáčková D, et al. Among authors: jeziskova i. Leukemia. 2024 Apr;38(4):893-897. doi: 10.1038/s41375-024-02215-9. Epub 2024 Mar 12. Leukemia. 2024. PMID: 38472478 Free PMC article. No abstract available.
Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients.
Durinikova A, Folta A, Pardy F, Svaton J, Drncova M, Weinbergerova B, Cetkovsky P, Racil Z, Jindra P, Szotkowski T, Zak P, Mayer J, Jeziskova I. Durinikova A, et al. Among authors: jeziskova i. Leuk Lymphoma. 2022 Dec;63(13):3237-3240. doi: 10.1080/10428194.2022.2116931. Epub 2022 Sep 1. Leuk Lymphoma. 2022. PMID: 36047997 No abstract available.
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Hornak T, Mayer J, Cicatkova P, Semerad L, Kvetkova A, Klamova H, Faber E, Belohlavkova P, Karas M, Stejskal L, Cmunt E, Cerna O, Srbova D, Zizkova H, Vrablova L, Skoumalova I, Voglova J, Jurkova T, Chrapava M, Jurcek T, Jeziskova I, Jarosova M, Machova Polakova K, Papajik T, Zak P, Jindra P, Zackova D. Hornak T, et al. Among authors: jeziskova i. Am J Hematol. 2024 Apr;99(4):763-766. doi: 10.1002/ajh.27229. Epub 2024 Feb 5. Am J Hematol. 2024. PMID: 38317312
Genesis of new allele at locus D2S1360 in leukemia patient.
Robesova B, Jeziskova I, Krejci M, Mayer J, Dvorakova D. Robesova B, et al. Among authors: jeziskova i. Leuk Lymphoma. 2017 Nov;58(11):2741-2744. doi: 10.1080/10428194.2017.1307363. Epub 2017 Apr 3. Leuk Lymphoma. 2017. PMID: 28367668 No abstract available.
Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.
Razga F, Jurcek T, Jeziskova I, Zackova D, Dvorakova D, Borsky M, Mayer J, Racil Z. Razga F, et al. Among authors: jeziskova i. Mol Diagn Ther. 2012 Jun 1;16(3):163-6. doi: 10.2165/11632420-000000000-00000. Mol Diagn Ther. 2012. PMID: 22489663
A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel.
Šestáková Š, Cerovská E, Šálek C, Kundrát D, Ježíšková I, Folta A, Mayer J, Ráčil Z, Cetkovský P, Remešová H. Šestáková Š, et al. Among authors: jeziskova i. Clin Epigenetics. 2022 Feb 11;14(1):22. doi: 10.1186/s13148-022-01242-6. Clin Epigenetics. 2022. PMID: 35148810 Free PMC article.
35 results